KLDO (OTC)
KALEIDO BIOSCIENCES INC
$0.000100
+0.000000 (+0.00%)
Prev close: $0.000100
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel L. Menichella, MBA
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $0.00M
- Employees
- 76
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
2
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2021 (Q4)
|
$-0.47 | $-0.59 | +0.1216 | +20.55% |
|
Sep 2021 (Q3)
|
$-0.54 | $-0.55 | +0.0125 | +2.26% |
|
Jun 2021 (Q2)
|
$-0.56 | $-0.58 | +0.0173 | +3.00% |
|
Mar 2021 (Q1)
|
$-0.58 | $-0.61 | +0.0259 | +4.27% |
Financial Statements
| Revenues | $1.10M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $88.77M |
| Nonoperating Income/Loss | -$2.62M |
| Operating Expenses | $88.77M |
| Research and Development | $67.80M |
| Other Operating Expenses | $20.97M |
| Operating Income/Loss | -$87.67M |
| Income/Loss From Continuing Operations After Tax | -$90.29M |
| Income/Loss From Continuing Operations Before Tax | $1.10M |
| Interest Expense, Operating | $2.84M |
| Net Income/Loss | -$90.29M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$90.29M |
| Net Income/Loss Available To Common Stockholders, Basic | -$90.29M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $50.14M |
| Current Assets | $42.31M |
| Noncurrent Assets | $7.83M |
| Fixed Assets | $5.67M |
| Other Non-current Assets | $2.16M |
| Liabilities | $39.53M |
| Current Liabilities | $29.68M |
| Accounts Payable | $5.67M |
| Wages | $1.88M |
| Other Current Liabilities | $22.13M |
| Noncurrent Liabilities | $9.85M |
| Equity | $10.61M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $10.61M |
| Liabilities And Equity | $50.14M |
| Net Cash Flow From Operating Activities | -$77.09M |
| Net Cash Flow From Operating Activities, Continuing | -$77.09M |
| Net Cash Flow From Investing Activities | -$691.00K |
| Net Cash Flow From Investing Activities, Continuing | -$691.00K |
| Net Cash Flow From Financing Activities | $70.04M |
| Net Cash Flow From Financing Activities, Continuing | $70.04M |
| Net Cash Flow | -$7.75M |
| Net Cash Flow, Continuing | -$7.75M |
| Comprehensive Income/Loss | -$90.29M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$90.29M |
| Other Comprehensive Income/Loss | $0.00 |